352 Target modulation within the tumor microenvironment (TME) by daratumumab (anti-CD38) but not edicotinib (CSF-1R inhibitor) in men with high-risk localized prostate cancer

• Shalini Singh,
• James Allison,
• Padmanee Sharma,
• Sumit Subudhi,
• Christopher Logothetis,
• Sonali Jindal,
• Curtis Pettaway,
• John Ward,
• Paul Corn,
• Bilal Siddiqui,
• Brian Chapin,
• Fei Duan,
• Rebecca Tidwell

Affiliations

Shalini Singh

3 ICMR - National Institute of Cancer Prevention and Research, Noida, India

James Allison

Aff2 grid.240145.60000000122914776MD Anderson Cancer Center Houston TX USA

Padmanee Sharma

Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Sumit Subudhi

Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center Division of Cancer Medicine, Houston, Texas, USA

Christopher Logothetis

Aff1 grid.240145.60000000122914776The University of Texas MD Anderson Cancer Center Houston TX USA

Sonali Jindal

The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Curtis Pettaway

1MD Anderson Cancer Center, Houston, TX, USA

John Ward

2E-Health Research Consortium

Paul Corn

2University of Texas MD Anderson Cancer Center, Houston, TX, USA

Bilal Siddiqui

MD Anderson Cancer Center, Houston, TX, USA

Brian Chapin

MD Anderson Cancer Center, Houston, TX, USA

Fei Duan

MD Anderson Cancer Center, Houston, TX, USA

Rebecca Tidwell

MD Anderson Cancer Center, Houston, TX, USA